Tuberculosis Diagnostics Market (2025-2032)
The Tuberculosis Diagnostics Market was valued at $2.41 billion in 2024. This market is expected to reach $3.56 billion by 2032, from an estimated $2.54 billion in 2025, at a CAGR of 5% during the forecast period 2025-2032. Tuberculosis Diagnostics Market Size & Forecast The growth of this market
- Published
- May 2024
- Pages
- 260
- Format
- PDF + Excel
- Report ID
- MR-1202
- Base year
- 2024
- 2024 · BASELINE
- $2.41B
- 2032
- $3.56B
- CAGR 2025–2032
- 5%
2024 baseline · 2025–2032 forecast at 5% CAGR · hover a bar for the value
Key highlights
By Test Type: In 2025, the Skin Test/Mantoux Segment to Dominate the Tuberculosis Diagnostics Market
By Infection Stage: In 2025, the Active Segment to Dominate the Tuberculosis Diagnostics Market
By End User: In 2025, the Diagnostic Laboratories Segment to Dominate the Tuberculosis Diagnostics Market
Report summary
| Particulars | Details |
|---|---|
| Page No | 260 |
| Format | |
| Forecast Period | 2025-2032 |
| Base Year | 2024 |
| CAGR | 5% |
| Market Size (Value) | $3.56 billion by 2032 |
| Segments Covered | By Test type · Skin Test/Mantoux · Interferon Gamma Release Assay · Radiographic Tests · Chest X-rays · Computed Tomography · Molecular Tests · Rapid Diagnostic Tests · Whole-genome Sequencing · Nucleic Acid Amplification Test · Other Molecular Tests (Sangers Sequencing, Pyrosequencing) · Sputum Smear Microscopy · Culture & Drug resistance · Other Test Types · (Note: Other Test Types include Urine Test, Breath Test, Cytokine Detection Assay, Cerebrospinal Fluid Test) · By Infection Stage · Active · Latent · By End User · Diagnostic Laboratories · Hospitals & Clinics · Other End Users · (Note: Other End Users include governments, private organizations, and NGOs) |
| Countries Covered | North America (U.S., Canada), Europe (Germany, France, U.K., Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Indonesia, Thailand, Philippines, South Korea, Australia, Singapore, Rest of APAC), Latin America, Middle East, and Africa (South Africa, Nigeria, Kenya, Rest of Africa) |
| Key Companies | F. Hoffmann-La Roche Ltd. (Switzerland), Becton, Dickinson and Company (U.S.), Abbott Laboratories, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), QIAGEN GmbH (Germany), Hologic, Inc. (U.S.), bioMérieux SA (France), Danaher Corporation (U.S.), Oxford Immunotec Ltd. (U.K.), Hain Lifescience GmbH (Germany), Creative Diagnostics (U.S.) |
Report overview
Segments covered: test type, end user, infection stage. Regions: North America, Europe, Asia-Pacific.
The growth of this market can be attributed to the rising prevalence of tuberculosis (TB) in low—and middle-income countries, the emergence of drug-resistant strains, and favorable initiatives for TB diagnosis and treatment. Moreover, initiatives by governments and organizations to raise awareness regarding tuberculosis are expected to generate growth opportunities for the players operating in the tuberculosis diagnostics market.
Market dynamics
4 factors across 3 forcesRising Prevalence of Tuberculosis in Low- and Middle-Income Countries
Around a quarter of the global population is estimated to have been infected with TB bacteria. According to the World Health Organization (WHO), in 2022, around 1.3 million people succumbed to tuberculosis (TB) globally. Moreover, 10.6 million people fell ill from TB in 2022 globally. However, the middle- and low-income countries have the highest TB burden, accounting for 80% of total deaths caused by TB. In 2022, the largest number of new TB cases occurred in WHO’s Southeast Asian Region, accounting for 46%, the African Region, accounting for 23%, and the Western Pacific region, accounting for 18%. Around 87% of new TB cases occurred in the 30 high TB-burden countries, with more than two-thirds of the global total in Bangladesh, China, the Democratic Republic of the Congo, India, Indonesia, Nigeria, Pakistan, and the Philippines.
Reducing the TB burden in low- and middle-income countries is expected to lead to the adoption of diagnostic tests for early diagnosis and treatment, driving market growth.
Table of contents
11 chapters · 110 sections · 260 pages · click to expandSegmental analysis
| Segment | Largest share (2025) | Fastest growth (2025–2032) |
|---|---|---|
| By Test Type | Skin Test/Mantoux | Molecular tests |
| By Infection Stage | Active | Active |
| By End User | Diagnostic Laboratories | Diagnostic laboratories |
By Test Type
- The Skin Test/Mantoux Segment to Dominate the Tuberculosis Diagnostics Market
- The skin test segment is expected to account for the largest share of 38.2% of the tuberculosis diagnostics market.
- The large market share of this segment is attributed to the ease and simplicity of the test, cost-effectiveness, and the ability to test for latent infections.
- However, the molecular tests segment is projected to register the highest growth rate of 5.8% during the forecast period of 2025–2032.
- The segment’s growth is driven by the high efficiency and accuracy of molecular tests, technological advancements in molecular diagnostic technology, increasing availability of molecular tests for TB, and initiatives by the companies to introduce rapid molecular diagnostic tests for TB & drug resistance.
- Moreover, the new guidelines by public organizations such as the WHO regarding molecular TB tests further drive the segment’s growth.
- For instance, in March 2025, the WHO published recommendations on the use of a new class of diagnostic technologies: targeted next-generation sequencing (NGS) tests for the diagnosis of drug-resistant tuberculosis (TB).
By Infection Stage
- The Active Segment to Dominate the Tuberculosis Diagnostics Market
- The active segment is expected to account for the larger share of 52.0% of the tuberculosis diagnostics market.
- The large share of the segment is attributed to the large burden of active cases globally, rising awareness regarding tuberculosis, and favorable initiatives for TB diagnosis and treatment.
- For instance, on 24th March 2024, the Stop TB Partnership hosted by the United Nations Office for Project Services (UNOPS) released a toolkit called “Yes!
- We Can End TB.” This toolkit was launched to bring attention to TB and the efforts to end TB by the year 2032.
- Similarly, the active segment is expected to register the highest CAGR during the forecast period of 2025-2032.
- This segment’s growth is attributed to the increasing prevalence of tuberculosis in low- and middle-income countries, aims and goals set by the governments and public organizations to manage the TB burden, and growing instances of TB outbreaks.
- For instance, in May 2025, the City Council in Long Beach, California (U.S.) declared a health emergency due to the outbreak of TB in the city.
- Moreover, as of April 29, 2025, 14 cases were found infected, and around 170 people were exposed.
By End User
- The diagnostic laboratories segment is expected to account for the largest share of the market.
- The availability of a wide menu of tests, rising awareness regarding TB, and increased identification of TB cases due to prompt testing contribute to the segment’s large share.
- The diagnostic laboratories segment is also expected to register the highest CAGR during the forecast period.
- This segment’s growth is attributed to favorable initiatives to raise awareness regarding TB and the launch of new diagnostic tests for TB and drug resistance.
- For instance, in January 2024, Molbio Diagnostics Pvt.
- Ltd. (India) launched the Treunat MTB-INH to test the presence of isoniazid resistance in Mycobacterium tuberculosis bacteria.
Geographic analysis
North America
Largest shareIn 2025, North America is expected to account for the largest share of 34.1% of the tuberculosis diagnostics market. Among the U.S. and Canada, in 2025, the U.S. is expected to account for the largest share of the tuberculosis diagnostics market in North America. The region’s large share is attributed to the high awareness regarding TB, routine TB testing for latent infections by the people traveling to the TB burdened countries, and adoption of advanced diagnostic methods.
Asia-Pacific
Fastest growthHowever, Asia-Pacific is slated to register the highest CAGR of 6.6% during the forecast period. Among the countries in the Asia-Pacific region, India and China are expected to register the highest CAGR during the forecast period. This growth is attributed to favorable government initiatives to strengthen the TB diagnostic infrastructure in the countries, aiming towards the eradication of TB and increasing awareness regarding TB.
Competitive landscape
- November 2024
Revvity, Inc. (U.S.) launched its T-SPOT.TB test for latent TB screening in India.
- October 2024
The Serum Institute of India launched a point-of-care skin test for detecting latent tuberculosis infections.
- April 2024
Boditech Med Inc. (South Korea) entered into an agreement with the Menarini Group (Italy). Under this agreement, Menarini will be the exclusive distributor of Boditech’s AFIAS-10 Single Test Immuno-Assay System, including IGRA-Tuberculosis, in 34 European countries.
- F. Hoffmann-La Roche Ltd. · Switzerland
- Becton
- Dickinson and Company (U.S.)
- Abbott Laboratories, Inc. (U.S.)
- Thermo Fisher Scientific, Inc. (U.S.)
- QIAGEN GmbH · Germany
- Hologic, Inc. (U.S.)
- Danaher Corporation (U.S.)
- Oxford Immunotec Ltd. (U.K.)
- Hain Lifescience GmbH · Germany
- Creative Diagnostics (U.S.)
Frequently asked questions
The tuberculosis diagnostics market covers the sizes & forecasts by test type, infection stage, and end user. This report studies the market by analyzing the value of various segments and sub-segments at regional and country levels.
Cite this report
Meticulous Research. (2024). Tuberculosis Diagnostics Market - Global Opportunity Analysis and Industry Forecast (2025-2032) (Report No. MR-1202). Meticulous Market Research Pvt. Ltd. https://www.meticulousresearch.com/product/tuberculosis-diagnostics-market-5885